BIOCITECH, France and KOBE, Japan - October the 15th, 2007 - Cellectis SA, the rational genome engineering company developing a new range of custom DNA rewriting products for the research, healthcare and industrial sectors, and TransGenic Inc, the tool providing company in the field of pharmaceutical and diagnostic development with its innovative technology of producing genetically engineered mice and a wide variety of antibody products, today announced that they entered into a non-exclusive license agreement under a patent family (JP 3059481, JP 3298842 and JP 3298864) relating to a process for the specific replacement or insertion of a gene in a receiver genome by homologous recombination.
